Literature DB >> 11196178

Expression of cyclooxygenase 2 in human malignant melanoma.

C Denkert1, M Köbel, S Berger, A Siegert, A Leclere, U Trefzer, S Hauptmann.   

Abstract

Cyclooxygenase (COX)-2 is an inducible enzyme involved in production of prostaglandins in inflammatory processes. There is now increasing evidence that a constitutive expression of COX-2 plays a role in development and progression of malignant epithelial tumors. In the present study we investigated expression and function of COX-2 in malignant melanoma. Expression of COX-2 was determined by immunohistochemistry in 28 cases of primary skin melanoma and 4 benign nevi. We show that COX-2 was expressed in 26 cases (93%) of melanomas, with a moderate to strong expression in 19 cases (68%). Benign nevi as well as normal epithelium were negative in all cases. A constitutive expression of COX-2 mRNA and protein was found in five melanoma cell lines (A375, MeWo, SK-Mel-13, SK-Mel-28, and IGR-37) by using Northern blot as well as immunoblotting. All melanoma cell lines produced prostaglandin (PG) E2 between 468 and 3500 pg/ml as determined by ELISA. Treatment with NS-398 (50 microM), a specific inhibitor of COX-2, suppressed PGE2 production of all melanoma cell lines by 50-96%. The IC50 for inhibition of PGE2 production by NS-398 was determined as 4 microM, indicating that NS-398 acts via inhibition of the COX-2 isoenzyme. We could show that proliferation of melanoma cell lines was not influenced by treatment with NS-398 in concentrations up to 100 microM. However, NS-398 reduced Matrigel invasion of all five malignant melanoma cell lines by 50-68%. Our results indicate that COX-2 is expressed in malignant melanomas and may be involved in regulation of melanoma invasion. It remains to be investigated whether selective inhibitors of COX-2 might be useful for prevention or treatment of malignant melanoma.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11196178

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  65 in total

Review 1.  Coffee consumption and the risk of cutaneous melanoma: a meta-analysis.

Authors:  Jia Wang; Xutong Li; Dongfeng Zhang
Journal:  Eur J Nutr       Date:  2015-12-22       Impact factor: 5.614

2.  Phase I/II study of selective cyclooxygenase-2 inhibitor celecoxib as a radiation sensitizer in patients with unresectable brain metastases.

Authors:  Leandro C A Cerchietti; Marcelo R Bonomi; Alfredo H Navigante; Monica A Castro; Maria E Cabalar; Berta M C Roth
Journal:  J Neurooncol       Date:  2005-01       Impact factor: 4.130

3.  Revisiting CB1 receptor as drug target in human melanoma.

Authors:  István Kenessey; Balázs Bánki; Agnes Márk; Norbert Varga; József Tóvári; Andrea Ladányi; Erzsébet Rásó; József Tímár
Journal:  Pathol Oncol Res       Date:  2012-03-24       Impact factor: 3.201

4.  An inhibitor of stress-activated MAP-kinases reduces invasion and MMP-2 expression of malignant melanoma cells.

Authors:  Carsten Denkert; Antje Siegert; Anja Leclere; Andreas Turzynski; Steffen Hauptmann
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

Review 5.  Immune-phenotypical markers for the differential diagnosis of melanocytic lesions.

Authors:  Gerardo Botti; Laura Marra; Annamaria Anniciello; Giosuè Scognamiglio; Vincenzo Gigantino; Monica Cantile
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

6.  Cyclooxygenase-2 and inducible nitric oxide synthase expression in thyroid neoplasms and their clinicopathological correlation.

Authors:  Kyung-Hee Kim; Seong-Ho Kim; Seok Hyung Kim; Jong-Ho Back; Mee-Ja Park; Jin-Man Kim
Journal:  J Korean Med Sci       Date:  2006-12       Impact factor: 2.153

7.  Docosahexaenoic acid, G protein-coupled receptors, and melanoma: is G protein-coupled receptor 40 a potential therapeutic target?

Authors:  Deepika Nehra; Amy H Pan; Hau D Le; Erica M Fallon; Sarah J Carlson; Brian T Kalish; Mark Puder
Journal:  J Surg Res       Date:  2014-01-29       Impact factor: 2.192

Review 8.  Current and future trials of targeted therapies in cutaneous melanoma.

Authors:  Matthew S Evans; Subbarao V Madhunapantula; Gavin P Robertson; Joseph J Drabick
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

9.  Tumoral and macrophage uPAR and MMP-9 contribute to the invasiveness of B16 murine melanoma cells.

Authors:  Chiara Marconi; Francesca Bianchini; Antonella Mannini; Gabriele Mugnai; Salvatore Ruggieri; Lido Calorini
Journal:  Clin Exp Metastasis       Date:  2007-12-11       Impact factor: 5.150

10.  A large cohort study of nonsteroidal anti-inflammatory drug use and melanoma incidence.

Authors:  Maryam M Asgari; Sonia S Maruti; Emily White
Journal:  J Natl Cancer Inst       Date:  2008-06-24       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.